Scleroderma Therapeutics Market: Market Dynamics, Key Developments, Future Scope, Industry Outlook

Scleroderma Therapeutics Market is estimated to reach at a CAGR of 5.98% during the forecast period (2024-2031).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/scleroderma-therapeutics-market?kb

Latest M&A

✅ Johnson & Johnson continues to expand its autoimmune portfolio but no major scleroderma-specific M&A announced in last 3 months. Broader pharma M&A is active with numerous companies investing in fibrosis and autoimmune portfolios.

Key Players:

Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals Holdings, Inc., Bayer AG, Gilead Sciences, Inc., Allergan, Inc., Pfizer, Inc., Sanofi, GlaxoSmithKline plc, Cumberland Pharmaceuticals, Inc and Actelion Pharmaceuticals, Inc.

Latest Drugs and Product Launches

✅ FDA granted traditional approval to Darzalex Faspro (daratumumab and hyaluronidase-fihj) for AL amyloidosis, an important therapeutic extension relevant due to fibrosis overlap in scleroderma.​

✅ Novartis and Pfizer maintain strong portfolios for systemic sclerosis (SSc) and ILD biologics, with ongoing late-stage pipelines targeting fibrotic pathways.

✅ Biotechs like Certa Therapeutics are advancing fibrosis-modulating drugs such as FT011 with positive Phase 2b data in systemic sclerosis patients

Growth Forecast Projection:

The Global Scleroderma Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Scleroderma Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=scleroderma-therapeutics-market?kb

Key Segmentation:

By Drug Class: (Immunosuppressors, Phosphodiesterase 5 Inhibitors - PHA, Endothelin Receptor Antagonists (ERA), Prostacyclin Analogues (PA), Calcium Channel Blockers (CCBs), Analgesics, Others)

By Indication: (Systemic, Localized)

By Distribution Channel: (Retail Stores, Online Stores, Hospitals, Others)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Latest Investments

The US scleroderma therapeutics market was valued at USD 1.16 billion in 2025 and forecasted to grow steadily with increasing investment in targeted biologics, immunomodulators, and precision medicine.​

Japan scleroderma market reached USD 99 million in 2024 with 7.5% CAGR, boosted by government incentives, orphan drug designations, and collaboration among pharma and academic centers.

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Scleroderma Therapeutics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Scleroderma Therapeutics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/scleroderma-therapeutics-market?kb

Latest Clinical Trials

✅ Kyverna Therapeutics initiated open-label phase 1/2 trials of KYV-101, a novel fully human CD19 CAR T-cell therapy targeting B-cell mediated autoimmune diseases including scleroderma.​

✅ Multiple ongoing trials include drugs like rituximab, tocilizumab, and nintedanib for systemic sclerosis and related ILD, with real-world studies emerging in Japan confirming efficacy and safety.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/scleroderma-therapeutics-market?kb

Project Hubs

✅ USA: Leading centers like the Scleroderma Foundation-supported clinical trials network, NIH-funded fibrosis therapeutic initiatives, and university hospitals in Boston, San Francisco, and New York.​

✅ Japan: University hospitals in Tokyo, Osaka, and Kyoto, in close collaboration with pharmaceutical companies such as Novartis and Kyverna Therapeutics, focusing on clinical trials and biologic development for scleroderma

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.